glp-1 kidney outcomes news Receptor Agonists and Diabetic Disease: A Call of Attention to Nephrologists GLP-1 drugs cut heart and

NHS Englands initial goal was to prescribe the weight loss drugs to no more than 220,000 people over three years

In the first half of 2024, LegitScript has already seen almost as many (94%) new healthcare merchant applications as we saw in all of 2023

Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss

Injectable versions dominated the category for years because peptides in pill form typically break down stomach acid before reaching the bloodstream

For diabetic retinopathy, the evidence was nuanced, indicating potential long-term neurovascular protection but also a risk of transient early worsening

And stay GLP-1 wise